Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience

I. Innocenti, F. Morelli, F. Autore, A. Piciocchi, A. Frustaci, F.R. Mauro, L. Schiattone, L. Trentin, G. Del Poeta, G. Reda, G.M. Rigolin, A. Ibatici, S. Ciolli, M. Coscia, P. Sportoletti, R. Murru, L. Levato, M. Gentile, G. D'Arena, D.G. EfremovA. Tedeschi, L. Scarfò, A. Cuneo, R. Foà, L. Laurenti

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e8-e11
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - 2019


  • ibrutinib
  • idelalisib
  • venetoclax
  • cancer growth
  • cancer mortality
  • cancer survival
  • chronic lymphatic leukemia
  • controlled study
  • drug withdrawal
  • human
  • Italy
  • Kaplan Meier method
  • Letter
  • major clinical study
  • multiple cycle treatment
  • overall survival
  • priority journal
  • progression free survival
  • retrospective study
  • treatment duration
  • treatment outcome
  • unspecified side effect

Cite this